Regulatory

Notice to AGM for Biovica International AB

The Board of Directors of Biovica International AB, corporate identity number 556774-6150, hereby convenes the Annual General Meeting on 27 August 2020 at 16:00 in the company’s premises at Dag Hammarskjölds väg 54B, Uppsala Science Park, Uppsala.

July 22, 2020

Biovica International AB – Annual Report for the fiscal year 2019/2020 published

Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ Contact Anders Rylander, CEOPhone: +46-18-444 48 35E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO/HR/IRPhone +46-73-125 92 47E-mail: cecilia.driving@biovica.com Biovica – Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation […]

June 30, 2020

Biovica Year-end Report for 2019/2020:

Preparations for the launch of DiviTum® have started

June 5, 2020

Biovica provides market share target at today’s Capital Market Day

Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica’s market launch strategy and goals. Biovica is also providing a market share target three years after launch of DiviTum®.

May 11, 2020

DiviTum – first study published on CDK4/6 inhibitor against clinical results

Period: May-January 2019/2020

March 12, 2020

Q2 Interim report: Work with the FDA application progressing as planned

“The results from two additional studies with DiviTum® will be presented at San Antonio Breast Cancer Symposium, the world’s largest scientific conference on breast cancer”. – Anders Rylander, CEO of Biovica

December 5, 2019

Plan for 510(k) submission specified – Q1 Interim Report: May-July 2019/2020

SEK thousands  Q1 19/20  Q1 18/19  May-April 18/19  Net sales  367  914  3,005  Operating profit (loss)  -6,097  -3,956  -21,718  Profit (loss) for the period  -6,068  -4,028  -21,556  Earnings per share, after dilution  -0.33  -0.23  -1.18  Significant events during the first quarter  Targeted new share issue for SEK 60 million to European and Swedish institutional investors […]

August 29, 2019

Biovica International AB – Annual Report for the fiscal year 2018/2019 published

Biovica’s annual report for the fiscal year 2018/2019 is published on our website https://www.biovica.com/investor-relations/financials/

June 28, 2019

FDA-process and commercialization on track. New study results confirm the potential. Year-End Report (May-January 2018/2019)

SEK thousands Q4 18/19 Q4 17/18 May-April 18/19 May-April 17/18 Net sales 1,715 1,433 3,005 2,723 Operating profit (loss) -8,569 -4,132 -21,718 -17,956 Loss for the period -8,631 -4,176 -21,556 -18,010 Earnings per share, after dilution -0.47 -0.24 -1.18 -1.01

June 14, 2019

Announcement from Biovica’s extra general meeting

The extra general meeting (“EGM”) of Biovica International AB (publ) (“Biovica” or the “Company”) was held today on 2 May 2019 and the following resolutions were passed by the meeting. Resolution regarding approval of the board of directors’ resolution to issue new class B shares with deviation from the shareholders’ preferential rights

May 2, 2019